Biological medicines, or biologics, represent a significant portion of the pharmaceutical pipeline, accounting for 30% of new drug approvals and up to 50% of the industry’s pipeline. Unlike small molecules, biologics are larger and have more complexities to their pharmacokinetic and pharmacodynamic properties.
Certara’s Simcyp Biologics platform is specifically designed to address these complexities, enabling scientists to model diverse biologics modalities such as monoclonal antibodies, protein conjugates, Fc-fusion proteins, bispecifics, and other proteins and peptides.
